ERZOFRI
Live / Registered — Registered (as of 19 Sept 2023)
What this means for you
Registered since 19 Sept 2023. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 19 Sept 2029: the §8 declaration of use).
Record
- Serial number
- 97283540
- Registration number
- 7167058
- Mark type
- Word mark
- Filed
- 24 Feb 2022
- Published for opposition
- 04 Jul 2023
- Registered
- 19 Sept 2023
- Next maintenance filing
- §8 declaration of use, due by 19 Sept 2029 (grace period to 19 Mar 2030)
- Attorney of record
- Paulo A. de Almeida
Goods and services
- Class 005 — Pharmaceuticals: Medicines for human purposes for the treatment of schizophrenia in adults; medicines for human purposes for the treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; chemical preparations for pharmaceutical purposes, namely, for the treatment of schizophrenia in adults; chemical preparations for pharmaceutical purposes, namely, for treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; Biochemical medicines for the treatment of schizophrenia in adults; Biochemical medicines for the treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; pharmaceutical preparations for treatment of schizophrenia in adults; pharmaceutical preparations for treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; chemico-pharmaceutical preparations for treatment of schizophrenia in adults; chemico-pharmaceutical preparations for treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; Injectable pharmaceuticals for treatment of schizophrenia in adults; Injectable pharmaceuticals for treatment of schizoaffective disorder in adults as mono therapy and as an adjunct to mood stabilizers or antidepressants; antidepressants; dressings, medical
Owner
- LUYE INNOMIND PHARMA SHIJIAZHUANG CO., LTD., SHIJIAZHUANG CITY, CN
- GENEORA PHARMA (SHIJIAZHUANG) CO., LTD., SHIJIAZHUANG CITY, HEBEI PROVINCE, CN
- GENEORA PHARMA (SHIJIAZHUANG) CO., LTD., SHIJIAZHUANG CITY, HEBEI PROVINCE, CN
- GENEORA PHARMA (SHIJIAZHUANG) CO., LTD., SHIJIAZHUANG CITY, HEBEI PROVINCE, CN
- SHANDONG LUYE PHARMACEUTICAL CO., LTD., SHANDONG PROVINCE, CN
Prosecution history
- 11 Sept 2024 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 19 Sept 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 19 Sept 2023 — REGISTERED-PRINCIPAL REGISTER
- 04 Jul 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Jul 2023 — PUBLISHED FOR OPPOSITION
- 14 Jun 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 31 May 2023 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 24 May 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Apr 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Apr 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Apr 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 14 Apr 2023 — ASSIGNED TO LIE
- 15 Feb 2023 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 18 Jan 2023 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 06 Jan 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED